Viridian Therapeutics’ stock jumped Monday after the company unveiled another Phase 3 look at its potential competitor to ...

President-elect Donald Trump’s two picks for the Federal Trade Commission are likely to usher in more life sciences deals ...

HRSA on Friday warned Sanofi against implementing its planned rebate model for some of its outpatient drugs under the drug ...

A turbulent 2024 for Neurocrine is ending on a high note, after the biotech won FDA approval to treat congenital adrenal ...

Edgewise Therapeutics’ treatment candidate for several forms of muscular dystrophy has hit the primary endpoint in a ...

Biohaven reports BHV-1300's lowest dose reduced IgG by 60%+ in trial, below analysts' 70-80% target. Drug shows promise for ...

PureTech Health unveiled positive Phase 2b data on Monday for its idiopathic pulmonary fibrosis drug, which showed it can ...

Just days after winning FTC approval to take on three of Catalent’s facilities, Novo Nordisk said it is investing DKK 8.5 ...

Bristol Myers Squibb is ending a pair of cell therapy collaborations with Immatics and nixing a separate agreement with ...

FTC approves Novo Holdings' $16.5B Catalent acquisition. Deal includes selling 3 facilities to Novo Nordisk for $11B, despite ...